http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113372304-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-20 |
| filingDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113372304-B |
| titleOfInvention | Method for preparing Engelliflozin intermediate by using continuous flow tubular reactor |
| abstract | The invention relates to the technical field of medicine synthesis, in particular to a method for preparing an Engelliflozin intermediate by a continuous flow tubular reactor, which comprises the following steps: in a continuous flow tubular reactor, 5-halogenated-2-chlorobenzoic acid is subjected to chlorination reaction and Friedel-crafts reaction in sequence to generate a compound with a structure shown in a formula b; under the action of potassium hydroxide and DMSO, reacting the compound with the structure of the formula b with s-3-hydroxytetrahydrofuran to obtain a compound with the structure of the formula a; further adopting a continuous flow tubular reactor to perform reduction reaction with hydrogen under the catalytic action of Pd/C to synthesize a target product. The method adopts the continuous flow tubular reactor, greatly shortens the reaction steps, has high automation degree, convenient control, high reaction rate, high efficiency, time and labor cost saving, and higher yield and product purity, and can prepare the product in commercial scale. |
| priorityDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.